Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Apixaban superior to VKAs for major bleeding, stroke/STE and all-cause mortality Next Article
Ticagrelor in diabetic patients reduces CV events but increases major bleeding »
« Apixaban superior to VKAs for major bleeding, stroke/STE and all-cause mortality Next Article
Ticagrelor in diabetic patients reduces CV events but increases major bleeding »
Related Articles
July 28, 2022
Urocortin-2 a potential treatment target for HFpEF
February 17, 2021
Remote risk management programme effective and efficient
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy